NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

8299	Companies
114942	Keywords
55348	Articles
62469	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 06/02/2024 at 16:00, 5 months 18 days ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announces new data from Study 1100 showing disease control and tumor response in patients with R/M HNSCC treated with RT-activated NBTXR3 followed by anti-PD-1. Investor event scheduled on June 2nd

NANOBIOTIX Study 1100 R/M HNSCC RT-activated NBTXR3 Anti-PD-1
BRIEF

published on 05/28/2024 at 22:20, 5 months 23 days ago

NANOBIOTIX Presents New Data at ASCO 2024

Immunotherapy NANOBIOTIX NBTXR3 ASCO Phase 1
PRESS RELEASE

published on 05/28/2024 at 22:15, 5 months 23 days ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Nanobiotix to present new data from Phase 1 immunotherapy program at 2024 ASCO meeting followed by investor conference call. Details for the call provided

Investor Conference Call Immunotherapy ASCO 2024 NANOBIOTIX Phase 1
BRIEF

published on 05/23/2024 at 22:20, 5 months 28 days ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Biotechnology Cancer Treatment Webcast NANOBIOTIX Jefferies Global Healthcare Conference
PRESS RELEASE

published on 05/23/2024 at 22:15, 5 months 28 days ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
Nanobiotix to present at the Jefferies Global Healthcare Conference on June 5, 2024, with Bart Van Rhijn, CFO, participating in a fireside chat. Company pioneering physics-based approaches for cancer treatment

Cancer Treatment Biotechnology Company NANOBIOTIX Jefferies Global Healthcare Conference Physics-based Approaches
BRIEF

published on 05/21/2024 at 22:20, 5 months 30 days ago

Nanobiotix Announces Advancement in NBTXR3 Development and Strategic Collaboration

Biotechnology Cancer Therapy NANOBIOTIX NBTXR3 Janssen Collaboration
PRESS RELEASE

published on 05/21/2024 at 22:15, 5 months 30 days ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix announces progress in global NBTXR3 development collaboration, highlighting robust pipeline and pathway to long-term growth in cancer treatment. Updates include US FDA approvals and strategic study modifications

Cancer Treatment NANOBIOTIX NBTXR3 Global Development FDA Approvals
BRIEF

published on 05/14/2024 at 22:20, 6 months 6 days ago

NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE

published on 05/14/2024 at 22:15, 6 months 6 days ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients

Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol

Accesswire

Published on 11/21/2024 at 14:15, 18 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 33 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 33 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 33 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 33 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 16 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 18 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 32 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 17 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 57 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 35 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 13 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 48 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 48 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE